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Insulin secretion declines progressively before and during the
course of type 2 diabetes. Evidence indicates that this process is,
in part, secondary to increased requirement for insulin secretion
that is brought about by insulin resistance and by hyperglycemia.
The effects of over-secretion extend far beyond a mere reduction
of available insulin stores and may cause not only functional but
also structural damage. The time is ripe for clinical studies, which
explore the therapeutic potential of reducing over-secretion.
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Insulin release is deﬁcient in Type 2 diabetes. Genetic causes
of deﬁcient insulin secretion in Type 2 diabetes are well rec-
ognized [1, 2]. However, accumulating evidence indicates that
non-genetic factors are also at play, some of which are linked
to the metabolic abnormalities evolving with, or preceding dia-
betes. That such factors are important is suggested by the fact
that insulin deﬁciency worsens with the duration of diabetes [3,
4], such worsening being the major reason for deterioration of
metaboliccontrolandtheneedforinsulintreatmentthatevolves
in the course of the disease. Furthermore, a number of studies
have shown that adequate treatment of diabetes has beneﬁcial
effects on insulin secretion [5–9].
Chronic hyperglycemia and dyslipidemia are two metabolic
abnormalities that are proposed to negatively affect pancreatic
beta cells [10]. The negative effects are often referred to respec-
tively as “glucotoxicity” and “lipotoxicicty”. The importance
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of “glucotoxicity” is by now well established whereas that of
“lipotoxicity” is still under debate.
The mechanisms whereby chronic hyperglycemia affects
beta cell functions have not been fully elucidated. By analogy
with the role of glucose in diabetic complications, the glucose
molecule could be thought to interact directly with proteins or
other molecules producing glycation products [11] and could
be metabolized to products which cause oxidative stress [12].
Indeed, evidence has been forthcoming to that extent [12–14].
However, since the beta-cells are primarily engineered to re-
spond to even small elevations of glucose above fasting levels,
the possibility exists that chronic hyperglycemia exerts nega-
tive effects by enforcing a state of oversecretion in beta cells.
Evidence, to be reviewed here, indicates that such “beta cell ex-
haustion” is harmful to beta cell function and perhaps survival.
It follows that other conditions which separately or in concert
with hyperglycemia cause oversecretion could also be harmful.
Such conditions include insulin resistance and pharmacological
treatment with sulphonylurea compounds.
In the following, we will review some of the evidence for an
important role of oversecretion behind deﬁcient and dysregu-
lated insulin release in diabetes. Most, but not all, of this evi-
dence comes from animal studies. Possible mechanisms behind
oversecretion will be discussed and possible strategies to avert
oversecretion will be presented.
ANIMAL STUDIES: OVERSECRETION BY
HYPERGLYCEMIA RAPIDLY DESENSITIZES
BETA CELLS TO GLUCOSE
In 1986, Leahy, et al. reported that 48 h of marked hyper-
glycemiainnormalrats,achievedbymassiveglucoseinfusions,
153154 V. GRILL AND A. BJ¨ ORKLUND
produced almost total insensitivity to glucose when insulin re-
lease was subsequently measured from perfused pancreas [15].
The desensitizing effect was speciﬁc for glucose, other secret-
agogues, such as arginine exerting normal or even exaggerated
responses.Oneofus(V.G.)latershowedthatifglucose-induced
insulinsecretionduringtheglucoseinfusionwasblockedbythe
simultaneous infusion of diazoxide, then no desensitization oc-
curred; if anything, insulin responses to glucose were enhanced
[16]. Since the levels of hyperglycemia were kept the same in
experiments with or without diazoxide, it was concluded that
the desensitizing effect was not due to any effects of hyper-
glycemia per se. We considered the possibility that the decrease
in hyperinsulinemia brought about by diazoxide could be im-
portant. Indeed, the addition of a continuous insulin infusion to
the protocol with diazoxide diminished glucose-induced insulin
secretion [16]. However, in vitro studies with pancreatic islets
culturedovernightwithdiazoxideatlowandhighglucoserepro-
duced the beneﬁcial effects of diazoxide but did not reveal any
effect of exogenously added insulin during culture [17]. There-
fore we concluded that beta cell over-secretion was the cause of
desensitization to glucose.
Studiesinanotheranimalmodel,the90%pancreatectomized
rat have also used diazoxide as a probe for assessing oversecre-
tion [18]. Also in this animal model did the results indicate a
profound inﬂuence of over-secretion on beta cell function.
ANIMAL STUDIES: OVERSECRETION BY
HYPERGLYCEMIA PRODUCES LASTING
EFFECTS ON BETA CELL FUNCTION
Thedesensitizingeffectsofupto48hofhyperglycemiawere
shown to be reversible within 24-h [15]. The question arises
whether chronic over-stimulation over months and years would
produce more lasting effects. In support of this notion, we ob-
tained evidence for a lasting effect of diazoxide treatment on
B-cell function in a rat transplantation model [19]. Islets from
normal rats were transplanted under the kidney capsule to syn-
geneic recipients previously made diabetic by streptozotocin.
Diazoxide treatment of these rats for 8 weeks improved trans-
plant function in terms of arginine-induced insulin secretion not
only during, but also when tested one week after treatment,
implying that over-stimulation had permanently damaged the
transplanted B-cells.
THE GK RAT
The GK rat is a non-obese model of type 2 diabetes in which
deﬁcient insulin secretion is at least the major cause of diabetes
[20]. Culture of pancreatic islets from these animals with di-
azoxide failed to restore a normal insulin secretion, despite a
resulting increase in intra-islet insulin contents [21]. Also in-
sulin treatment at early age did not improve insulin secretion at
later age [22]. The most likely explanation for these ﬁndings is
that the genetic determinants of deﬁcient insulin secretion are
strong enough to override any effect of modulating the demands
for insulin secretion.
HUMAN STUDIES IN VITRO
In human pancreatic islets we found that 48-h of tissue cul-
ture at a high glucose concentration completely desensitized
glucose-induced insulin secretion [23] and that this desensitiza-
tion could be corrected by co-culture with diazoxide. We also
demonstrated that over-secretion is coupled to a preferential in-
creaseofproinsulinreleaseandpresenceintheislets.Cultureof
humanpancreaticisletsfor48hat27mMglucosethusmarkedly
increased the ratio of immunoreactive proinsulin to insulin in
islets as well as in secreted products both during and after cul-
ture [23]. Furthermore, the increased ratio both of stored and
secreted products was completely normalized by blocking in-
sulin secretion with diazoxide. These results are analogous to
those in rat pancreas of 90% pancreatectomized rats, receiving
or not receiving diazoxide [24].
HUMAN STUDIES IN VIVO
As previously mentioned, there are many studies in type 2
diabetic patients which demonstrate that correction or at least
amelioration of hyperglycemia can improve insulin secretion
[5–9]. None of these studies however were designed to sep-
arately evaluate oversecretion vs. other effects. Therefore, one
cannotapriorideducetheparticipationofoversecretionorrelief
thereof. Only one published study using glucose infusions and
somatostatin to suppress endogenous insulin secretion attests to
a beneﬁcial effect of avoiding oversecretion [25]. However, our
observations in human islets that oversecretion in vitro is asso-
ciated with preferential release and storage of proinsulin could
render proinsulin or ratios of proinsulin to insulin in plasma
a valid marker of oversecretion. It is well known that a pref-
erential increase of proinsulin in plasma is a hallmark of type
2 diabetes and that these parameters vary with the degree of
metabolic control [26] and strain on the beta cell [27]. The va-
lidity of proinsulin being a marker for oversecretion is strength-
ened by a large population-based epidemiological study [28]
in which over 3000 subjects were screened for glucose toler-
ance insulin secretion, insulin resistance and proinsulin. The
results of the study negated any role of genetics behind levels
of proinsulin. Furthermore, the study showed a tight correspon-
dence between the degree of insulin resistance and proinsulin
levels.
Diazoxidehasbeentestedinanopenshorttermstudyintype
2 diabetes with promising effects on beta cell function [29];OVER-SECRETION AND DIABETES 155
however, a follow-up study reported that the drug caused in-
sulin resistance [30]. Such resistance was not encountered in
a study in newly diagnosed subjects with type 1 diabetes [31].
Subjects were treated for 3 months with placebo or with dia-
zoxide 4–6 mg/kg body weight in divided doses. Endogenous
insulin secretion, as measured by C-peptide glucagon tests was
better preserved in diazoxide-treated than in placebo-treated
subjects three times up to one year after the end of diazoxide
treatment. Thus, the treatment effect was considerable. How-
ever, in the previous studies side effects of diazoxide (edema,
hair growth, hypotension, and nausea) have been considerable.
These side effects are not serious and are reversible. How-
ever, they are disturbing enough to impede further long-term
studies.
OVERSECRETION AND INSULIN RESISTANCE
Insulin resistance increases demands for insulin secretion,
adding to the demands of hyperglycemia. The question arises
whether insulin resistance per (or in the presence of only min-
imal hyperglycemia) could have harmful effects linked to beta
cell oversecretion. Certainly, longitudinal data in type 2 dia-
betes, for instance in Pima Indians [32] are compatible with
such a notion, insulin resistance preceding at least a major
deﬁciency in insulin secretion. However, again it is not pos-
sible from such studies to deduce any speciﬁc inﬂuence of
oversecretion vis-` a-vis other inﬂuences. Also compatible with
harmful effects of oversecretion are epidemiological data in
Pima Indians showing that the duration of obesity (a marker
of insulin resistance) is a risk factor for diabetes and low in-




nylurea in treatment of type 2 diabetes patients may be ques-
tioned. Indeed, in vitro evidence from beta cells demonstrate
negative effects of prolonged exposure to SU [35]. However,
putative negative effects of SU during long term treatment on
insulin secretion have so far not been speciﬁcally investigated.
in man. To evaluate any such effect would require that one takes
into consideration any change in metabolic control which could
per se alter insulin secretion.
In order to speciﬁcally examine long term effects of SU on
insulin secretion in man we randomized newly diagnosed type
2 diabetic patients to either glibenclamide or insulin treatment
[36]. Insulin release as measured from C-peptide glucagon tests
was signiﬁcantly better in the insulin-treated group after one
year of the study but not signiﬁcantly so after 2 years of the
study. Later follow-ups will determine whether the two treat-
ments differ in the long run in terms of preservation of beta cell
function.
MECHANISMS BEHIND EFFECTS OF
OVERSECRETION
In previous studies one usually ﬁnds a reduction of insulin
contents in islets or perfused pancreas, which is concomitant
with desensitization. Therefore, it has been proposed that in-
sulin depletion fully explains the decrease in glucose-induced
insulin secretion [37], in which case the term “desensitization”
may not be appropriate for the phenomenon. However, with
regard to studies with diazoxide, several observations indicate
that the protective effects of the drug on desensitization are only
partly explained by preservation of insulin contents. In this con-
text, cooling experiments in rat islets are instructive. Cooling
below 30 degrees Celsius inhibits exocytosis of insulin but only
marginally decreases glucose-induced Ca2C inﬂow during glu-
cose stimulation [38]. We found that cooling during glucose
stimulation,whileblockinginsulinsecretionandupholdingislet
insulin contents, only partially protected against desensitization
[17]. Only after exclusion of Ca2C in the incubation media did
coolingcompletelyprotectagainstdesensitization.Theseresults
support the notion that persistent inﬂow of Ca2C—and/or cellu-
lar events following that inﬂow but distinct from exocytosis—is
negative for B cell functions and participates in the desensitiza-
tion due to over-stimulation.
Further support for effects not linked to insulin depletion
comes from recent experiments in a diabetic transplantation
model. The model is similar to the one described above, ex-
cept that the graft-bearing recipients were moderately rather
than severely diabetic. Treatment with diazoxide for 8 weeks
was followed by one week of no treatment. Grafts from rats
previously receiving diazoxide were then signiﬁcantly more re-
sponsive both to glucose and to nonnutrient secretagogues than
grafts from placebo-treated rats, whereas insulin contents were
comparable(unpublishedobservations).Inthiscontextitiswor-
thy of note that insulin secretion in type 2 diabetes is reduced
far out of proportion to any reduction in insulin content or beta
cell mass [39].
Deposition of amyloid in pancreatic islets could be patho-
genetically important in type 2 diabetes. It is well known that
amyloid accumulates in type 2 diabetic subjects [40]. It prob-
ably interferes with normal beta cell function. Animal studies
indicate that an inﬂuence of hyperglycemia on amyloid deposi-
tion is indirect. For example, animals with glukokinase muta-
tions develop diabetes because of inability of elevated glucose
to activate the enzyme, which in turn blocks the glucose signal
for insulin secretion. These animals in whom hyperglycemia is
caused by under-secretion from a normal number of beta cells
seem protected from the formation of amyloid [41].156 V. GRILL AND A. BJ¨ ORKLUND
RELEVANCE OF DIAZOXIDE AS A PROBE FOR
TESTING OVERSECRETION
As evident from the fore going, much although not all, evi-
dence for the importance of over-secretion comes from studies
using diazoxide. The question arises whether drug effects that
are not related to protection from oversecretion could also come
into play. The inhibitory effect of diazoxide on insulin secretion
stems from the activation of the drug of ATP-dependent potas-
sium channels in the cell membrane of beta cells [42]. These
effects are the opposite of those of glucose and thereby coun-
teract the stimulating effects of glucose on insulin secretion.
Diazoxide was chosen as a probe for oversecretion, because a)
its inhibitory effects on insulin secretion are rapidly reversible,
b) the drug has been used in clinical medicine without serious
toxicity, c) the inhibitory effects during the presence of diazox-
ide are more pronounced than the effects of other inhibitors,
such as somatostatin and adrenaline. In our hands we did not
observe any beneﬁcial effects of diazoxide on beta cell function
during non-stimulatory conditions, i.e. after the presence of the
drug during low-glucose conditions. Nevertheless, some effects
of the drug per se cannot be wholly excluded. In this context it
should be mentioned that diazoxide during its presence in high
concentrations decreases mitochondrial membrane potential in
beta cells [43]. It was also reported that diazoxide during its
presence protects beta cells from streptozotocin toxicity [44].
Furthermore, in heart muscle diazoxide exerts direct effects on
mitochondria which are coupled to some degree of protection
against myocardial ischemia [45, 46]. Diazoxide may also have
beneﬁcial effects in other tissues [47]. It could be conjectured
thatdiazoxideconfersbyasyetundeﬁnedmechanismsaheight-
eneddefenseagainstoxidativestresswhichisdemonstrableonly
in situations of increased oxidative stress; such as exposure to
toxins and to hyperglycemia. However, studies by ourselves in-
dicate that the beneﬁcial effects of diazoxide that we observe
in vitro can be mimicked by somatostatin, which inhibits in-
sulin secretion by mechanisms totally different from those of
diazoxide [48].
FUTURE DIRECTIONS OF CLINICAL
RESEARCH ON OVERSTIMULATION
There is general consensus that present therapies in type 2
diabetes are not sufﬁcient to uphold good metabolic control in
the course of the disease and that new therapeutic modalities are
needed. As reviewed above, there is by now much experimental
evidencelinkingover-stimulationwithbetacelldemise.Luckily
from a therapeutic perspective the situation seems much more
amenable to treatment than in the GK animal model of type 2
diabetes, in which the progression of diabetes may be geneti-
cally determined. In our view, the time is therefore ripe for new
clinical studies which target the role of over-stimulation and the
clinical importance of “beta cell rest” in type 2 diabetes. One
way to achieve “beta cell rest” is to increase insulin sensitiv-
ity. This can be done pharmacologically with metformin and
with the newly developed thiozoladindiones, such as rosiglita-
zone and pioglitazone. Compatible with this notion metformin
can delay onset of type 2 diabetes [49]. Another way is to use
drugs such as diazoxide in the treatment of type 2 diabetes. The
clinical use of diazoxide is hampered by the drug’s side effects.
However, the doses so far used may well be higher than those
that would signiﬁcantly “rest” beta cells and improve beta cell
function. There is also the possibility that analogues of diazox-
ide could produce lesser side effects. At least one such analogue
is presently undergoing testing [44].
Lastly it should be pointed out that any intervention to im-
prove insulin secretion should start early in the disease when
endogenous insulin secretion (and presumably the number of
functional beta cells) has not decreased too far. Evidence in-
dicates that it would be far too late to await the stage when
metabolic control has deteriorated to the point where insulin
supplementation is considered, in which case the possibility of
improving beta cell function by any means is very limited [50].
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